ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAE
1
Trial Info
2
Week26/10/2015
3
Study ID20
4
Journal nameBMJ
5
Trial Title
Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
6
Trial Linkhttp://www.bmj.com/content/bmj/351/bmj.h5364.full.pdf
7
Publication date28/10/2015
8
Registry linkhttps://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001941-42/SE
9
Registry ID
EudraCT 2012-001941-42
10
Protocol link, if availablehttps://drive.google.com/open?id=0B2r5CjEdwpx_RlF6UXJvMk9oWTQ
Note: last revised for publication 23/07/2014, trial commenced Feb 2013. Therefore, pre-specified outcomes here are taken from the trial registry entry, given above.
11
12
13
Prespecified Primary OutcomeCorrectly reported in main trial results tables?Incorrectly reported in main trial results tablesNot reported in tables, but reported elswhere in paper?Not reported in journal publication
14
1
Primary endpoint will be change in HbA1c from baseline to week 24.
Yes
15
2
16
3
17
4
18
5
19
20
Total1TOTALS1
21
22
Prespecified Secondary OutcomeCorrectly reported in main trial results tables?Incorrectly reported in main trial results tablesNot reported in tables, but reported elswhere in paper?Not reported in journal publication
23
1Change in weight from baseline to week 24Yes
24
2Change in fasting glucose from baseline to week 24Yes
25
3Change in the standard deviation of CGM from the run-in period to week 23-24Yes
26
4
Change in mean glucose levels on CGM from the run-in period to week 23-24
Yes
27
5
Change in 1.5 hour postprandial glucose levels on capillary glucose measurements from the run-in period to week 23-24
Yes
28
6
Change in the score of the DTSQs from baseline to week 24
Yes
29
7
Score of the DTSQc at week 24
Yes
30
8
Proportion of patients with HbA1c less than 8.0% (64 mmol/mol) at week 24
Yes
31
9
Proportion of patients with HbA1c less than 7.5% (58 mmol/mol) at week 24
Yes
32
10
Change in total insulin dose from baseline to week 24
Yes
33
11
Proportion of patients with HbA1c less than 7.0% (53 mmol/mol) at week 24
Yes
34
12
Change in blood pressure from baseline to week 24
Yes
35
13
Frequency of non-severe documented symptomatic hypoglycaemia (plasma glucose [PG] less than 4.0 mmol/l) from baseline to week 24
Yes
36
14
Frequency of asymptomatic non-severe hypoglycaemia (PG less than 4.0 mmol/l) from baseline to week 24
Yes
37
15
Frequency of non-severe documented symptomatic hypoglycaemia (PG less than 3.0 mmol/l) from baseline to week 24
Yes
38
16
Frequency of asymptomatic non-severe hypoglycaemia (PG less than 3.0 mmol/l) from baseline to week 24
Yes
39
17
Frequency of severe hypoglycaemia from baseline to week 24
Yes
40
18
Change in blood lipid levels from baseline to week 24
Yes
41
42
Total18TOTALS18
43
44
Non-prespecified outcome in publicationCorrectly reported as non-pre-specified in tables?Not reported
45
1
46
2
47
3
48
4
49
5
50
6
51
7
52
8
53
9
54
10
55
11
56
12
57
58
Total0TOTALS
59
60
Complications to trial and issues arising in free text
61
They have broken up some of their categories into multiple subcategories. For HbA1c target, they have shown significance at three realistic levels rather than just one. For No. of hypoglycaemic episodes, they have shown no significant increase in episodes at 5 different severity levels.
Lipid levels are broken up into 4 categories, all not significantly improved (ie they haven't cherry-picked the one that showed most improvement), and blood pressure levels were significantly reduced in systole, but not diastole. Again, they could have chosen to report only Systolic BP.
I feel the addition of CGM mean and DTSQ total score trivial, and does not warrant a letter.
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100